Global Cancer Institute has extended its programs to Bangladesh, with the launch of new monthly tumor boards that help physicians and oncologists in developing countries connect directly to U.S. physicians by videoconference to discuss challenging cancer cases and ask for advice.
After receiving a stage 4 colon cancer diagnosis, author Ibram X. Kendi sought consultation at two hospitals located a mile apart.
Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?
Venclexta (venetoclax) has received FDA approval in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy.
Tagrisso receives FDA Priority Review for adjuvant treatment of early-stage EGFR-mutated lung cancer
Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application and has also been granted Priority Review by FDA for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
A study conducted by Avalere Health shows a considerable drop in cancer screening, diagnosis, and treatment for American seniors and Medicare beneficiaries in 2020.
A clinical guideline from the American Society for Radiation Oncology provides guidance for physicians who use radiation therapy to treat patients with locally advanced rectal cancer.
In March 2020, as the scope of the coronavirus pandemic became evident, the effects of a public health crisis rippled throughout every industry and facet of daily life.
Walter J. (Wally) Curran, Jr. said he would step down as executive director of Winship Cancer Institute of Emory University to serve as the global chief medical officer of GenesisCare, an international group described as “the world's largest provider of radiation oncology care and a major global provider of other medical services.”
Mark Bonnen was named chief medical officer at Mays Cancer Center at UT Health San Antonio.
